Reporting and Analysis Plan - Evaluation of Secondary Malignancies in Patients Treated with Dabrafenib in Randomized, Controlled Trials (201710)First published 25/08/2014 Last updated 14/03/2024 EU PAS number: EUPAS7317StudyFinalised
Clinical Disclosure Officer Clinical Disclosure OfficerStudy contacttrialandresults.registries@novartis.com